E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
non melanoma skin cancer |
nicht melanozytäre Hauttumore |
|
E.1.1.1 | Medical condition in easily understood language |
superficial skin cancer |
oberflächlicher Hautkrebs |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10004146 |
E.1.2 | Term | Basal cell carcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the efficacy of photodynamic therapy in combination with 5% Imiquimod versus photodynamic monotherapy in patients with non melanoma skin cancer |
Der Vergleich der Effektivität einer photodynamischen Monotherapie versus einer photodynamischen Therapie in Kombination mit 5% Imiquimod bei Patienten mit nicht-melanozytären Hauttumoren |
|
E.2.2 | Secondary objectives of the trial |
To compare the tolerability, relapse rate, patients' satisfaction, cosmetic result and the clinical response rates after treatment with photodynamic monotherapy versus photodynamic therapy in combination with 5%Imiquimod |
Vergleich der Effektivität, Rezidivrate und des kosmetischen Ergebnisses einer photodynamischen Monotherapie versus einer photodynamischen Therapie in Kombination mit 5% Imiquimod bei Patienten mit nicht-melanozytären Hauttumoren |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients with clinically confirmed non melanoma skin cancer elswhere on the body Age 18 years or older |
Patienten mit nicht melanozytären Hauttumoren Patienten über 18 Jahre
|
|
E.4 | Principal exclusion criteria |
known allergy to imiquimod and aminolevulinic acid patients who are participating in another study patients with instable organ function pregnant or lactating women patients unable to stick to the study protocoll patients with severe compromised general state Patients with porphyria or taking photosensitizing drugs |
Porphyrie oder Einnahme von photosensibilisierenden Medikamenten Unverträglichkeit von Imiquimod oder Aminolävulinsäure schwere Beeinträchtigung des Allgemeinzudtandes Patienten die an einer anderen Studie teilnehmen Unvermögen, den Behandlungsplan zu bewältigen bzw den Pflichten des Studienteilnehmers nachzukommen schwangere und stillende Frauen |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percentage of non-melanoma skin tumors cleared 3 months after completion of treatment in both groups |
Prozentsatz von abgeheilten nicht-melanozytären Hauttumoren 3 Monate nach Beendigung der Therapie in beiden Gruppen |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Clinical control after 3, 6 and 12 months after treatment with PDT or PDT mono or in combination with Imiquimod |
klinische Kontrollen 3, 6 sowie 12 Monate nach durchgeführter MonoPDT oder PDT in Kombination mit Imiquimod |
|
E.5.2 | Secondary end point(s) |
The recurrence rate of non-melanoma skin cancer at 6 and 12 months after completion of therapy in both treatment groups. Cosmetic response and global patients satisfaction. |
Die Rezidivrate von nicht melanozytären Hauttumoren nach 6 und 12 monaten nach Beendigung der Therapie in beiden behandelten Gruppen. Kosmetisches Ergebnis und Patientenzufriedenheit |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Recurrence rate 6 and 12 months after completion of therapy in both treatment groups cosmetic response and global patients' satisfaction 3, 6, and 12 months after completion of therapy in both treatment groups
|
Rezidivrate von nicht melanozytären Hauttumoren 6 und 12 Monate nach Beendigung der Therapie in beiden behandelten Gruppen. kosmetische Beurteilung sowie globale Patientenzufriedenheit 3, 6 und 12 Monaten nach Beendigung der Therapie in beiden Gruppen
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
end of the trial after completion of the follow up examination 12 month after therapy of 40 participants |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | 0 |